Generics BulletinCipla may have lagged some peers when it comes to its biosimilars foray in the US, but things appear to be picking up momentum and an evolving regulatory environment could potentially aid pipeline tra
ScripCipla may have lagged some peers when it comes to its biosimilars foray in the US, but things appear to be picking up momentum and an evolving regulatory environment could potentially aid pipeline tra
Generics BulletinTariffs are a key topic these days at biopharma events and things were no different at Cipla’s annual general meeting (AGM), especially amid US president Donald Trump’s continued threat and changing t
ScripTariffs are a key topic these days at biopharma events and things were no different at Cipla’s annual general meeting (AGM), especially amid US President Donald Trump’s continued threat and changing t